| Product name: |
LATS1/2 (phospho Thr1079/1041) rabbit pAb |
| Reactivity: |
Human;Mouse |
| Alternative Names: |
LATS1; WARTS; Serine/threonine-protein kinase LATS1; Large tumor suppressor homolog 1; WARTS protein kinase; h-warts; LATS2; KPM; Serine/threonine-protein kinase LATS2; Kinase phosphorylated during mitosis protein; Large tumor suppressor ho |
| Source: |
Rabbit |
| Dilutions: |
Immunohistochemistry: 1/100 – 1/300. ELISA: 1/20000. Not yet tested in other applications. |
| Immunogen: |
The antiserum was produced against synthesized peptide derived from human LATS1/2 around the phosphorylation site of Thr1079/1041. AA range:1041-1090 |
| Storage: |
-20C/1 year |
| Clonality: |
Polyclonal |
| Isotype: |
IgG |
| Concentration: |
1 mg/ml |
| Molecular Weight: |
125kD |
| GeneID: |
9113/26524 |
| Human Swiss-Prot No: |
O95835/Q9NRM7 |
| Cellular localization: |
Cytoplasm, cytoskeleton, microtubule organizing center, centrosome . Cytoplasm, cytoskeleton, spindle . Midbody . Cytoplasm, cytoskeleton, microtubule organizing center, spindle pole body . Localizes to the centrosomes throughout interphase but migrates to the mitotic apparatus, including spindle pole bodies, mitotic spindle, and midbody, during mitosis. . |
| Background: |
The protein encoded by this gene is a putative serine/threonine kinase that localizes to the mitotic apparatus and complexes with cell cycle controller CDC2 kinase in early mitosis. The protein is phosphorylated in a cell-cycle dependent manner, with late prophase phosphorylation remaining through metaphase. The N-terminal region of the protein binds CDC2 to form a complex showing reduced H1 histone kinase activity, indicating a role as a negative regulator of CDC2/cyclin A. In addition, the C-terminal kinase domain binds to its own N-terminal region, suggesting potential negative regulation through interference with complex formation via intramolecular binding. Biochemical and genetic data suggest a role as a tumor suppressor. This is supported by studies in knockout mice showing development of soft-tissue sarcomas, ovarian stromal cell tumors and a high sensitivity to carcinogenic treatmen |
